396 related articles for article (PubMed ID: 28758855)
1. Targeting DNA hypermethylation: Computational modeling of DNA demethylation treatment of acute myeloid leukemia.
Przybilla J; Hopp L; Lübbert M; Loeffler M; Galle J
Epigenetics; 2017; 12(10):886-896. PubMed ID: 28758855
[TBL] [Abstract][Full Text] [Related]
2. Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts.
Gozzini A; Santini V
Ann Hematol; 2005 Dec; 84 Suppl 1():54-60. PubMed ID: 16228241
[TBL] [Abstract][Full Text] [Related]
3. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells.
Flotho C; Claus R; Batz C; Schneider M; Sandrock I; Ihde S; Plass C; Niemeyer CM; Lübbert M
Leukemia; 2009 Jun; 23(6):1019-28. PubMed ID: 19194470
[TBL] [Abstract][Full Text] [Related]
4. 5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation.
Scott SA; Dong WF; Ichinohasama R; Hirsch C; Sheridan D; Sanche SE; Geyer CR; Decoteau JF
Leuk Res; 2006 Jan; 30(1):69-76. PubMed ID: 16043219
[TBL] [Abstract][Full Text] [Related]
5. Reexpression of epigenetically silenced AML tumor suppressor genes by SUV39H1 inhibition.
Lakshmikuttyamma A; Scott SA; DeCoteau JF; Geyer CR
Oncogene; 2010 Jan; 29(4):576-88. PubMed ID: 19881540
[TBL] [Abstract][Full Text] [Related]
6. Combination treatment of acute myeloid leukemia cells with DNMT and HDAC inhibitors: predominant synergistic gene downregulation associated with gene body demethylation.
Blagitko-Dorfs N; Schlosser P; Greve G; Pfeifer D; Meier R; Baude A; Brocks D; Plass C; Lübbert M
Leukemia; 2019 Apr; 33(4):945-956. PubMed ID: 30470836
[TBL] [Abstract][Full Text] [Related]
7. Signatures of polycomb repression and reduced H3K4 trimethylation are associated with p15INK4b DNA methylation in AML.
Paul TA; Bies J; Small D; Wolff L
Blood; 2010 Apr; 115(15):3098-108. PubMed ID: 20190193
[TBL] [Abstract][Full Text] [Related]
8. DNMT inhibitors reverse a specific signature of aberrant promoter DNA methylation and associated gene silencing in AML.
Lund K; Cole JJ; VanderKraats ND; McBryan T; Pchelintsev NA; Clark W; Copland M; Edwards JR; Adams PD
Genome Biol; 2014 Aug; 15(8):406. PubMed ID: 25315154
[TBL] [Abstract][Full Text] [Related]
9. Redistribution of H3K27me3 and acetylated histone H4 upon exposure to azacitidine and decitabine results in de-repression of the AML1/ETO target gene IL3.
Buchi F; Masala E; Rossi A; Valencia A; Spinelli E; Sanna A; Gozzini A; Santini V
Epigenetics; 2014 Mar; 9(3):387-95. PubMed ID: 24300456
[TBL] [Abstract][Full Text] [Related]
10. Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and -negative myeloid leukemia cell lines.
Berg T; Guo Y; Abdelkarim M; Fliegauf M; Lübbert M
Leuk Res; 2007 Apr; 31(4):497-506. PubMed ID: 17056112
[TBL] [Abstract][Full Text] [Related]
11. Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting.
Schafer E; Irizarry R; Negi S; McIntyre E; Small D; Figueroa ME; Melnick A; Brown P
Blood; 2010 Jun; 115(23):4798-809. PubMed ID: 20215641
[TBL] [Abstract][Full Text] [Related]
12. Identification of coexistence of DNA methylation and H3K27me3 specifically in cancer cells as a promising target for epigenetic therapy.
Takeshima H; Wakabayashi M; Hattori N; Yamashita S; Ushijima T
Carcinogenesis; 2015 Feb; 36(2):192-201. PubMed ID: 25477340
[TBL] [Abstract][Full Text] [Related]
13. Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?
Lowder JN; Taverna P; Issa JP
Epigenomics; 2015 Oct; 7(7):1083-8. PubMed ID: 26541345
[No Abstract] [Full Text] [Related]
14. Change in gene expression profiles of secreted frizzled-related proteins (SFRPs) by sodium butyrate in gastric cancers: induction of promoter demethylation and histone modification causing inhibition of Wnt signaling.
Shin H; Kim JH; Lee YS; Lee YC
Int J Oncol; 2012 May; 40(5):1533-42. PubMed ID: 22246241
[TBL] [Abstract][Full Text] [Related]
15. Hypermethylation of CpG sites at the promoter region is associated with deregulation of mitochondrial ATPsyn-β and chemoresistance in acute myeloid leukemia.
Yang J; Xiao X; Li R; Li Z; Deng M; Zhang G
Cancer Biomark; 2016; 16(1):81-8. PubMed ID: 26835708
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of ID4 by promoter hypermethylation in gastric adenocarcinoma.
Chan AS; Tsui WY; Chen X; Chu KM; Chan TL; Chan AS; Li R; So S; Yuen ST; Leung SY
Oncogene; 2003 Oct; 22(44):6946-53. PubMed ID: 14534543
[TBL] [Abstract][Full Text] [Related]
17. Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia.
Fabiani E; Leone G; Giachelia M; D'alo' F; Greco M; Criscuolo M; Guidi F; Rutella S; Hohaus S; Voso MT
Leuk Lymphoma; 2010 Dec; 51(12):2275-84. PubMed ID: 21077739
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agents.
Claus R; Almstedt M; Lübbert M
Semin Oncol; 2005 Oct; 32(5):511-20. PubMed ID: 16210092
[TBL] [Abstract][Full Text] [Related]
19. Histone acetylation together with DNA demethylation empowers higher plasticity in adipocytes to differentiate into osteoblasts.
Cho YD; Kim BS; Kim WJ; Kim HJ; Baek JH; Woo KM; Seol YJ; Ku Y; Ryoo HM
Gene; 2020 Apr; 733():144274. PubMed ID: 31809844
[TBL] [Abstract][Full Text] [Related]
20. DNA methylation as a therapeutic target in hematologic disorders: recent results in older patients with myelodysplasia and acute myeloid leukemia.
Rüter B; Wijermans PW; Lübbert M
Int J Hematol; 2004 Aug; 80(2):128-35. PubMed ID: 15481440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]